Anixa Biosciences Inc (ANIX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Anixa Biosciences Inc (ANIX) has a cash flow conversion efficiency ratio of -0.134x as of July 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.77 Million) by net assets ($13.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see ANIX stock market capitalisation for the company's overall valuation and market capitalisation.
Anixa Biosciences Inc - Cash Flow Conversion Efficiency Trend (1989–2025)
This chart illustrates how Anixa Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Anixa Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Anixa Biosciences Inc ranked by their cash flow conversion efficiency. Explore how high is Anixa Biosciences Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chyang Sheng Dyeing & Finishing Co Ltd
TW:1463
|
0.003x |
|
China Container Terminal Corp
TW:2613
|
0.063x |
|
Optiscan Imaging Ltd
AU:OIL
|
-0.188x |
|
Hansol Holdings Co Ltd
KO:004150
|
0.010x |
|
Lexinfintech Holdings Ltd
NASDAQ:LX
|
0.081x |
|
Shanghai Phoenix Enterprise Group Co Ltd B
SHG:900916
|
0.036x |
|
Catur Sentosa Adiprana Tbk
JK:CSAP
|
0.036x |
|
Adisyn Ltd
AU:AI1
|
-0.042x |
Annual Cash Flow Conversion Efficiency for Anixa Biosciences Inc (1989–2025)
The table below shows the annual cash flow conversion efficiency of Anixa Biosciences Inc from 1989 to 2025. View ANIX stock price and chart for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $13.95 Million | $-7.17 Million | -0.514x | -32.41% |
| 2024-10-31 | $18.89 Million | $-7.33 Million | -0.388x | -46.17% |
| 2023-10-31 | $23.37 Million | $-6.21 Million | -0.266x | -15.40% |
| 2022-10-31 | $28.20 Million | $-6.49 Million | -0.230x | -62.09% |
| 2021-10-31 | $34.77 Million | $-4.94 Million | -0.142x | +80.99% |
| 2020-10-31 | $8.26 Million | $-6.18 Million | -0.747x | +24.16% |
| 2019-10-31 | $4.81 Million | $-4.74 Million | -0.985x | -19.51% |
| 2018-10-31 | $5.18 Million | $-4.27 Million | -0.824x | -72.04% |
| 2017-10-31 | $7.92 Million | $-3.80 Million | -0.479x | +86.01% |
| 2016-10-31 | $987.48K | $-3.38 Million | -3.425x | -1369.40% |
| 2015-10-31 | $5.05 Million | $1.36 Million | 0.270x | +145.46% |
| 2014-10-31 | $4.01 Million | $-2.38 Million | -0.593x | -161.83% |
| 2013-10-31 | $-3.32 Million | $-3.19 Million | 0.960x | -63.51% |
| 2012-10-31 | $-1.19 Million | $-3.14 Million | 2.630x | +488.68% |
| 2011-10-31 | $1.06 Million | $-716.00K | -0.677x | -29.28% |
| 2010-10-31 | $4.60 Million | $-2.41 Million | -0.523x | +6.83% |
| 2009-10-31 | $4.45 Million | $-2.50 Million | -0.562x | -7.80% |
| 2008-10-31 | $1.73 Million | $-901.87K | -0.521x | +74.09% |
| 2007-10-31 | $1.19 Million | $-2.40 Million | -2.012x | -39.62% |
| 2006-10-31 | $1.28 Million | $-1.85 Million | -1.441x | +6.35% |
| 2005-10-31 | $1.12 Million | $-1.72 Million | -1.539x | -139.14% |
| 2004-10-31 | $1.87 Million | $-1.21 Million | -0.643x | -33.47% |
| 2003-10-31 | $1.99 Million | $-958.50K | -0.482x | -158.94% |
| 2002-10-31 | $2.32 Million | $-431.47K | -0.186x | -8.06% |
| 2001-10-31 | $4.17 Million | $-717.85K | -0.172x | +80.22% |
| 2000-10-31 | $5.56 Million | $-4.84 Million | -0.871x | +10.05% |
| 1999-10-31 | $6.30 Million | $-6.10 Million | -0.968x | -49.64% |
| 1998-10-31 | $11.90 Million | $-7.70 Million | -0.647x | -19.26% |
| 1997-10-31 | $18.80 Million | $-10.20 Million | -0.543x | -194.53% |
| 1996-10-31 | $22.80 Million | $-4.20 Million | -0.184x | +40.29% |
| 1995-10-31 | $9.40 Million | $-2.90 Million | -0.309x | +45.15% |
| 1994-10-31 | $6.40 Million | $-3.60 Million | -0.563x | -77.40% |
| 1993-10-31 | $8.20 Million | $-2.60 Million | -0.317x | +23.53% |
| 1992-10-31 | $4.10 Million | $-1.70 Million | -0.415x | -45.12% |
| 1991-10-31 | $4.20 Million | $-1.20 Million | -0.286x | -6.49% |
| 1990-10-31 | $4.10 Million | $-1.10 Million | -0.268x | -10.00% |
| 1989-10-31 | $4.10 Million | $-1.00 Million | -0.244x | -- |
About Anixa Biosciences Inc
Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer. The company also engaged … Read more